Pediatric Oncology

US News and World Report Ranking Badge
Erin Guest, MD, conducts research in a lab at Children's Mercy Cancer Center.

Pediatric Oncology


The Children's Mercy oncology program is a national leader in cancer treatment. Our program provides pediatric patients with comprehensive clinical services and innovative treatment (including Phase I Experimental Therapeutics, stem cell transplantation, and immunotherapies such as CAR T-cell) supported by the latest research. We provide advanced treatment for children with cancer including brain tumors, leukemia, lymphoma, solid tumors (including Neuroblastoma, Wilms, Liver, Germ Cell, etc.), bone and soft tissue tumors, histiocytic diseases, and vascular tumors.

Pediatric Oncologists & Specialists

We are committed to ongoing research to help develop new, more effective treatments for childhood cancer. Because of that commitment, our survival rates are frequently above national averages. Our care team includes more than 25 pediatric oncologists and hematology specialists. Dedicated nurse practitioners help coordinate each step of treatment. This includes chemotherapy, surgery, radiation, labs, and any other services patients and families need from the time of diagnosis until care is completed. Our team creates a care plan suited to each patient's individual treatment needs.  

Cancer Treatment Outcomes in Children

Our team is driven to continually improve treatment outcomes for pediatric cancers. The charts below reflect survival rates for specific types of cancers treated at Children's Mercy as well as frequency of diagnosis.

Five-year oncology outcomes

Oncology condition diagnosis frequency

The Division of Pediatric Hematology, Oncology and Bone Marrow Transplantation

Each year, the Division of Pediatric Hematology, Oncology and Bone Marrow Transplantation at Children’s Mercy Kansas City provides comprehensive care to nearly 2,000 children with childhood cancers, sickle cell disease, hemophilia and other blood disorders, with survival rates frequently above national averages. At any given time, the Division is participating in 80–100 clinical and laboratory trials, including several national trials led by its own investigators. As the primary pediatric cancer provider and the only NCI Children’s Oncology Group institution in the Midwest Cancer Alliance, Children’s Mercy is the pediatric consortium partner for the National Cancer Institute-designated The University of Kansas Cancer Center and the Stowers Institute for Medical Research. This partnership offers progress in cutting-edge cancer research to help the plight of children with cancer. The Division also has received accreditation from the American College of Surgeons Commission on Cancer and the Foundation for Accreditation of Cellular Therapy.

Copyright © 2017 The Children’s Mercy Hospital